Investor Presentaiton slide image

Investor Presentaiton

Our industry leading position in protein degradation is driven by portfolio breadth and depth of expertise Industry-leading capabilities Molecular glue Target protein Molecular glue molecule E3 ligase CELMOD evotec Berkeley UNIVERSITY OF CALIFORNIA Hetero- bifunctional Target protein ADC degrader Cysteine residue E3 ligase • Drug-Linker LDD SGC A-ALPHA BIO Full Development Early Development CELMOD ADC IND-enabling studies SyntheX Targeting the undruggable AMPHISTA THERAPEUTICS Industry-leading pipeline iberdomide: Multiple Myeloma golcadomide: Lymphoma CK1a: Acute Myeloid Leukemia BCL6 LDD: Lymphoma HbF CELMOD: Sickle Cell Disease CELMOD Solid Tumors Discuss today mezigdomide: Multiple Myeloma AR LDD: Prostate Helios: Solid Tumors LDD: Prostate LDD: Autoimmune >15 pre-clinical programs across multiple therapeutic areas Potential to efficiently deliver -4 INDS annually and expand beyond Heme/Onc targets (Immunology, CV, Neuroscience) Ill Bristol Myers Squibb™ Not for Product Promotional Use 34
View entire presentation